On June 7, 2021, the US Food and Drug Administration (FDA) finally made its decision on aducanumab, anti-amyloid drug that has been subject of a prolonged controversial approval process. Contrary to recommendation their Peripheral Central Nervous System Advisory Committee (PCNSDAC), FDA surprisingly approved aducanumab for treatment Alzheimer's disease. The ruling split neurology community, wit...